Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.40
-5.71 (-2.72%)
AAPL  266.47
+1.89 (0.71%)
AMD  196.12
-4.03 (-2.01%)
BAC  51.30
-1.76 (-3.32%)
GOOG  314.38
-0.52 (-0.17%)
META  642.99
-12.67 (-1.93%)
MSFT  386.12
-11.11 (-2.80%)
NVDA  190.98
+1.16 (0.61%)
ORCL  139.18
-8.90 (-6.01%)
TSLA  398.68
-13.14 (-3.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.